Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer

June 2-6, 2017; Chicago, Illinois

Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.

Format: Microsoft PowerPoint (.ppt)

File Size: 277 KB

Released: June 8, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings